Potent Growth-inhibitory Effect of TRAIL Therapy Mediated by Double-regulated Oncolytic Adenovirus on Osteosarcoma

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2012 Feb 23

PMID 22354724

Citations 5

Authors

Chunbao Li

Li Chunbao

Qianpeng Cheng

Cheng Qianpeng

Jia Liu

Liu Jia

Bin Wang

Wang Bin

Dongfeng Chen

Chen Dongfeng

Yujie Liu

Liu Yujie

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) severely threatens the health of young people and understanding on the molecular mechanisms of OS etiology enables gene therapy to become an effective therapeutic modality. However, insufficient expression level of genes using existing vectors limits the clinical application of gene therapy for OS. To solve the problem, we developed an oncolytic adenoviral vector, OAT, which can selectively and efficiently replicate in OS cells to enhance the expression of transferred genes. We demonstrated that OAT-mediated TRAIL expression is significantly elevated after infection of OS cells than replication-incompetent Ad5 vector. Increased antitumor capacity was observed in OS cells after OAT-TRAIL treatment both in vitro and in vivo. In normal cells, adenoviral replication, TRAIL expression and growth-inhibiting effect were quite limited when OAT-TRAIL was administrated, showing a high biosafety of this oncolytic adenoviral vector. Collectively, we generated an efficient and promising expression vector for OS gene therapy.

Citing Articles

TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment.

Brion R, Gantier M, Biteau K, Taurelle J, Brounais-Le Royer B, Verrecchia F Cancers (Basel). 2022; 14(22).

PMID: 36428719 PMC: 9688679. DOI: 10.3390/cancers14225627.

Adenovirus-mediated small interfering RNA targeting ezrin induces apoptosis and inhibits metastasis of human osteosarcoma MG-63 cells.

Tao Z, Zou P Biosci Rep. 2018; 38(4).

PMID: 29899165 PMC: 6131204. DOI: 10.1042/BSR20180351.

miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism.

Sun X, Geng X, Zhang J, Zhao H, Liu Y Mol Cell Biochem. 2015; 403(1-2):139-47.

PMID: 25666090 DOI: 10.1007/s11010-015-2344-z.

TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway.

Li R, Liu J, Wu H, Liu L, Wang L, Zhang S Mol Cell Biochem. 2014; 392(1-2):109-16.

PMID: 24771064 DOI: 10.1007/s11010-014-2023-5.

Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Takagi-Kimura M, Yamano T, Tagawa M, Kubo S Cancer Gene Ther. 2014; 21(3):126-32.

PMID: 24577130 DOI: 10.1038/cgt.2014.7.

References

Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V . Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007; 67(15):7308-18. DOI: 10.1158/0008-5472.CAN-06-4130. View

He X, Liu J, Yang C, Su C, Zhou C, Zhang Q . 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum Gene Ther. 2010; 22(3):283-92. DOI: 10.1089/hum.2010.058. View

Kim M, Sgagias M, Deng X, Jung Y, Rikiyama T, Lee K . Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression. Biochem Biophys Res Commun. 2004; 320(1):138-44. DOI: 10.1016/j.bbrc.2004.05.135. View

Dirice E, Sanlioglu A, Kahraman S, Ozturk S, Balci M, Omer A . Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther. 2009; 20(10):1177-89. DOI: 10.1089/hum.2009.039. View

Jiang X, Du L, Yang S, Chen L, Lu G . Suppression of teratocarcinoma growth by soluble TRAIL gene expression driven by the progression-elevated gene-3 promoter. Cancer Biol Ther. 2009; 8(15):1517-24. DOI: 10.4161/cbt.8.15.9005. View

Hemmati P, Gillissen B, Von Haefen C, Wendt J, Starck L, Guner D . Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene. 2002; 21(20):3149-61. DOI: 10.1038/sj.onc.1205458. View

Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R . Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res. 1999; (358):120-7. View

Ma L, Liu J, Shen J, Liu L, Wu J, Li W . Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010; 9(7):554-61. DOI: 10.4161/cbt.9.7.11267. View

Alemany R, Suzuki K, Curiel D . Blood clearance rates of adenovirus type 5 in mice. J Gen Virol. 2000; 81(Pt 11):2605-2609. DOI: 10.1099/0022-1317-81-11-2605. View

10.

Chou A, Geller D, Gorlick R . Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs. 2008; 10(5):315-27. DOI: 10.2165/00148581-200810050-00005. View

11.

Li X, Jung C, Liu Y, Bae K, Zhang Y, Zhang H . Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. J Gene Med. 2006; 8(6):679-89. DOI: 10.1002/jgm.904. View

12.

David E, Guihard P, Brounais B, Riet A, Charrier C, Battaglia S . Direct anti-cancer effect of oncostatin M on chondrosarcoma. Int J Cancer. 2011; 128(8):1822-35. DOI: 10.1002/ijc.25776. View

13.

Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y . Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res. 2008; 14(8):2450-7. DOI: 10.1158/1078-0432.CCR-07-4596. View

14.

He Q, Shi J, Shen X, An J, Sun H, Wang L . Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther. 2010; 9(10):819-24. DOI: 10.4161/cbt.9.10.11552. View

15.

Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V . Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010; 16(11):3035-43. DOI: 10.1158/1078-0432.CCR-09-3167. View

16.

Rojas J, Guedan S, Searle P, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F . Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther. 2010; 18(11):1960-71. PMC: 2990517. DOI: 10.1038/mt.2010.173. View

17.

Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A . Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14(7):1126-34. DOI: 10.1093/annonc/mdg286. View

18.

Yazawa M, Setoguchi A, Hong S, Uyama R, Nakagawa T, Kanaya N . Effect of an adenoviral vector that expresses the canine p53 gene on cell growth of canine osteosarcoma and mammary adenocarcinoma cell lines. Am J Vet Res. 2003; 64(7):880-8. DOI: 10.2460/ajvr.2003.64.880. View

19.

Hemminki A, Kanerva A, Kremer E, Bauerschmitz G, Smith B, Liu B . A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther. 2003; 7(2):163-73. DOI: 10.1016/s1525-0016(02)00049-7. View

20.

Seto M, Yamazaki T, Sonoda J, Matsumine A, Shinto Y, Uchida A . Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy. Oncol Rep. 2002; 9(2):337-40. View